Gramine Triggers Ferroptosis in TNBC via the CUL3–MTDH Axis

Study Background and Research Question

Triple-negative breast cancer (TNBC) is among the most aggressive and therapeutically challenging subtypes of breast cancer, defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER2 expression. Patients with TNBC often face poor prognoses and high recurrence rates due to limited targeted therapies and frequent development of chemotherapy resistance (source: internal_article). As a result, there is an urgent demand for novel, mechanism-driven therapeutic strategies. Natural small molecules have become a focal point in oncology research, given their structural diversity and multi-targeted pharmacology. Gramine (GM), a plant-derived indole alkaloid, has previously demonstrated anti-inflammatory, antimicrobial, and anticancer activities. However, its mechanisms against aggressive cancers such as TNBC have not been fully elucidated. This study sought to determine whether gramine could suppress TNBC cell growth and to uncover the molecular pathways involved, with a focus on cell death modalities such as ferroptosis (source: internal_article).

Key Innovation from the Reference Study

The principal innovation of this paper lies in the discovery that gramine directly targets the CUL3–MTDH axis to induce ferroptosis in TNBC cells. Specifically, the study reveals that gramine binds to the E3 ubiquitin ligase CUL3, modulating its activity toward MTDH (metadherin). This interaction leads to altered ubiquitination and stabilization of MTDH, which subsequently impacts key regulators of ferroptosis—namely, downregulation of the ferroptosis inhibitors SLC3A2 and GPX4 and upregulation of ferroptosis markers (source: internal_article). This mechanistic link between gramine, ubiquitin-mediated protein regulation, and ferroptotic cell death was previously uncharacterized in the context of TNBC.

Methods and Experimental Design Insights

The study implemented a multi-tiered experimental approach to establish both efficacy and mechanistic underpinnings:

• Compound Screening: A panel of 27 indole alkaloids was assessed using CCK-8 viability assays to identify growth inhibitors in TNBC cell lines 4T1 and MDA-MB-231.
• Target Validation: Direct binding of gramine to candidate proteins was confirmed using limited proteolysis-mass spectrometry (LIP-MS), molecular docking, cellular thermal shift assays (CETSA), and drug affinity-responsive target stability (DARTS) assays.
• Protein Expression and Ferroptosis Assessment: Western blots measured the expression of MTDH, SLC3A2, and GPX4. Ferroptosis was evaluated by quantifying reactive oxygen species (ROS), ferrous iron (Fe²⁺), malondialdehyde (MDA), reduced glutathione (GSH), and by analyzing mitochondrial morphology via electron microscopy.
• Mechanistic Rescue and Knockdown: Ferroptosis inhibitors and MTDH knockdown were used to rescue or reverse gramine’s effects, confirming the dependency of observed cytotoxicity on the CUL3–MTDH pathway.
• In Vivo Validation: The in vivo efficacy and safety profile of gramine were evaluated in murine xenograft models bearing TNBC tumors.

Protocol Parameters

• Cell viability assay | CCK-8, 24–48 h, 4T1/MDA-MB-231 | Determines gramine cytotoxicity | Standard for initial screening of drug candidates | paper
• Gramine IC₅₀ | 22–28 μM | TNBC cell lines | Demonstrates selective anti-TNBC potency | paper
• Protein digestion (sample prep) | Pronase E, ≥7000 U/g, 10–50 μg/mL | Proteomic workflows | Ensures broad-spectrum proteolysis for target identification | workflow_recommendation
• In vivo mouse dosage | 20–40 mg/kg, i.p., qd | TNBC xenograft model | Assesses tumor suppression and systemic toxicity | paper

Core Findings and Why They Matter

Gramine selectively inhibited TNBC cell proliferation, with half-maximal inhibitory concentrations (IC₅₀) ranging between 22 and 28 μM (source: internal_article). Proteomic and functional analyses identified the CUL3–MTDH axis as a direct target of gramine. Gramine binding suppressed CUL3-mediated ubiquitination of MTDH, resulting in MTDH stabilization. This led to the downregulation of SLC3A2 and GPX4 (inhibitors of ferroptosis) and a concomitant increase in ferroptosis-associated markers such as ROS, Fe²⁺, and MDA, together with mitochondrial morphological changes indicative of lipid peroxidation. Mechanistically, the induction of ferroptosis was verified by the ability of ferroptosis inhibitors and MTDH knockdown to rescue cell viability and reverse tumor suppression both in vitro and in xenograft models. Importantly, gramine administration in vivo resulted in significant tumor growth inhibition without observable systemic toxicity, highlighting translational promise. This work underscores the therapeutic value of targeting the CUL3–MTDH axis for ferroptosis-based strategies in recalcitrant breast cancers (source: internal_article).

Comparison with Existing Internal Articles

Several internal resources corroborate and contextualize the present findings. The article "Gramine Induces Ferroptosis in TNBC via CUL3–MTDH Ubiquitination" provides a mechanistic overview consistent with the present study, highlighting both the translational potential of gramine and the centrality of the CUL3–MTDH axis in ferroptosis regulation. Another article (see here) emphasizes the novelty of modulating ferroptosis through E3 ubiquitin ligase targeting in cancer therapy. In contrast, resources such as "Pronase E Protease Mixture: Structural Versatility in Proteomics" and "Pronase E Protease Mixture: Optimized Workflows for Proteomics" focus on technical advances in proteomics, including protein sample preparation and peptide mapping, which are relevant for the target identification and validation phases employed in this study.

Limitations and Transferability

While the study provides compelling evidence for gramine's anti-TNBC efficacy via ferroptosis, several limitations warrant consideration. First, the primary experiments were conducted in established TNBC cell lines and murine xenograft models, which may not fully recapitulate the heterogeneity of human tumors. Second, although the CUL3–MTDH pathway appears central, off-target effects or parallel pathways could contribute to the observed phenotypes and should be systematically investigated in future work. Finally, long-term safety and pharmacokinetics of gramine in larger animal models or clinical settings remain to be established. Nevertheless, the mechanistic insights into ferroptosis regulation may have broader applicability to other cancers with similar ferroptosis sensitivity profiles (source: internal_article).

Research Support Resources

For researchers aiming to replicate or extend similar mechanistic studies, robust protein sample preparation is essential, especially for proteomics and target identification workflows. A high-activity protease mixture such as Pronase E (Activity ≥ 7000 U/g) (SKU A9953, APExBIO) can facilitate broad-spectrum protein digestion, enabling efficient peptide mapping and analysis of post-translational modifications relevant to ubiquitination and ferroptosis research (source: internal_article). Pronase E is widely recognized as a reliable enzyme for protein sample preparation in biochemical and molecular biology research—freshly prepared solutions are recommended for optimal activity. For detailed protocol guidance, consult manufacturer recommendations and recent workflow publications.